当前位置: X-MOL 学术Nature › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
Structural pharmacology and therapeutic potential of 5-methoxytryptamines
Nature ( IF 64.8 ) Pub Date : 2024-05-08 , DOI: 10.1038/s41586-024-07403-2
Audrey L. Warren , David Lankri , Michael J. Cunningham , Inis C. Serrano , Lyonna F. Parise , Andrew C. Kruegel , Priscilla Duggan , Gregory Zilberg , Michael J. Capper , Vaclav Havel , Scott J. Russo , Dalibor Sames , Daniel Wacker

Psychedelic substances such as lysergic acid diethylamide (LSD) and psilocybin show potential for the treatment of various neuropsychiatric disorders1,2,3. These compounds are thought to mediate their hallucinogenic and therapeutic effects through the serotonin (5-hydroxytryptamine (5-HT)) receptor 5-HT2A (ref. 4). However, 5-HT1A also plays a part in the behavioural effects of tryptamine hallucinogens5, particularly 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), a psychedelic found in the toxin of Colorado River toads6. Although 5-HT1A is a validated therapeutic target7,8, little is known about how psychedelics engage 5-HT1A and which effects are mediated by this receptor. Here we map the molecular underpinnings of 5-MeO-DMT pharmacology through five cryogenic electron microscopy (cryo-EM) structures of 5-HT1A, systematic medicinal chemistry, receptor mutagenesis and mouse behaviour. Structure–activity relationship analyses of 5-methoxytryptamines at both 5-HT1A and 5-HT2A enable the characterization of molecular determinants of 5-HT1A signalling potency, efficacy and selectivity. Moreover, we contrast the structural interactions and in vitro pharmacology of 5-MeO-DMT and analogues to the pan-serotonergic agonist LSD and clinically used 5-HT1A agonists. We show that a 5-HT1A-selective 5-MeO-DMT analogue is devoid of hallucinogenic-like effects while retaining anxiolytic-like and antidepressant-like activity in socially defeated animals. Our studies uncover molecular aspects of 5-HT1A-targeted psychedelics and therapeutics, which may facilitate the future development of new medications for neuropsychiatric disorders.



中文翻译:

5-甲氧基色胺的结构药理学和治疗潜力

麦角酸二乙酰胺 (LSD) 和裸盖菇素等迷幻物质显示出治疗各种神经精神疾病的潜力1,2,3。这些化合物被认为是通过血清素(5-羟色胺(5-HT))受体 5-HT 2A介导其致幻和治疗作用(参考文献4)。然而,5-HT 1A也在色胺致幻剂的行为效应中发挥一定作用5,特别是 5-甲氧基-N,N-二甲基色胺 (5-MeO-DMT),这是一种在科罗拉多河蟾蜍毒素中发现的致幻剂6。尽管 5-HT 1A是经过验证的治疗靶点7,8 ,但人们对致幻剂如何作用 5-HT 1A以及该受体介导哪些作用知之甚少。在这里,我们通过 5-HT 1A的五种低温电子显微镜 (cryo-EM) 结构、系统药物化学、受体诱变和小鼠行为绘制了 5-MeO-DMT 药理学的分子基础。对 5-甲氧基色胺在 5-HT 1A和 5-HT 2A上的结构-活性关系分析能够表征 5-HT 1A信号传导效力、功效和选择性的分子决定因素。此外,我们还比较了 5-MeO-DMT 及其类似物与泛血清素激动剂 LSD 和临床使用的 5-HT 1A激动剂的结构相互作用和体外药理学。我们发现,5-HT 1A选择性 5-MeO-DMT 类似物在社交失败的动物中没有致幻作用,同时保留了抗焦虑和抗抑郁作用。我们的研究揭示了 5-HT 1A靶向致幻剂和疗法的分子方面,这可能有助于未来开发治疗神经精神疾病的新药物。

更新日期:2024-05-09
down
wechat
bug